05:39 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Renova to begin Phase III of RT-100 in heart failure

Renova Therapeutics (San Diego, Calif.) said it will start this quarter the Phase III FLOURISH trial of gene therapy RT-100 (Ad5.hAC6) to treat heart failure with reduced left ventricular ejection fraction (LVEF). The 12-month, double-blind,...
07:00 , Oct 6, 2016 |  BC Innovations  |  Product R&D

Encoding glucose control

Renova Therapeutics has licensed a gene therapy technology for Type II diabetes from the University of California San Diego that could control blood glucose levels for years with only a single injection. By discovering a...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Ad5: Phase II data

Top-line combined data from the 2 highest dose groups of RT-100 in a double-blind, U.S. Phase II trial in 56 symptomatic heart failure patients with an ejection fraction of <=40% showed that intracoronary RT-100 met...
01:01 , Mar 31, 2016 |  BC Extra  |  Clinical News

Renova raising funds for pivotal gene therapy trials

Renova Therapeutics (San Diego, Calif.) plans to begin three pivotal studies by YE16 of gene therapy candidate RT-100 to treat congestive heart failure (CHF), CEO Jack Reich told BioCentury. He said the company also hopes...